Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2011. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding their interests in the company's Ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of insider share transactions rather than a financial performance report.
Material Changes
The filing details the acquisition of Ordinary shares by nine individuals on January 6, 2011, at a price of £12.50 per share through the Company's Share Reward Plan. All acquisitions were made under the Dividend Reinvestment element of the Plan. The specific number of shares acquired by each individual ranged from 7 to 29 shares.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of share ownership changes in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Transaction Date: January 6, 2011.
- Share Price: £12.50 per Ordinary share.
- Transaction Mechanism: Dividend Reinvestment element of the Share Reward Plan.
- Participants: Nine Directors or Persons Discharging Managerial Responsibility, including Mr. A P Witty and Mr. J S Heslop.
- Notification Date: January 7, 2011.